Parse Biosciences and Graph Therapeutics Team Up to Map Immune System Responses at Scale
Event summary
- Parse Biosciences and Graph Therapeutics announced a partnership on January 20, 2026 to create one of the largest immune cell perturbation atlases.
- The collaboration will profile hundreds of millions of cells from patients with immune diseases using Graph's lab-in-the-loop platform and Parse's GigaLab technology.
- Goal is to accelerate AI-first drug discovery for immune-mediated diseases by reducing late-stage failures and development costs.
The big picture
This partnership addresses the challenge of patient-specific immune responses in drug development by combining sophisticated disease models with scalable single-cell analysis. The collaboration represents an industry trend toward using AI and large-scale biological data to overcome traditional limitations in translating preclinical findings to clinical success. The potential to reduce late-stage failures could significantly improve the economics of developing therapies for complex inflammatory diseases.
What we're watching
- Data Infrastructure
- How the partnership's data generation approach will impact drug development economics and success rates.
- Technological Integration
- Whether Graph's perturbation selection system can effectively complement Parse's single-cell sequencing capabilities.
- Market Differentiation
- The pace at which this collaboration could establish a competitive advantage in immune-mediated disease research.
Related topics